Skip to search formSkip to main contentSkip to account menu

CI 937

Known as: CI-937 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

AnthraquinonesAntineoplastic AgentsPyrazolesteloxantrone
Dup 937

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1989
1989
Development of a radioimmunoassay for the anthrapyrazole chemotherapy agent CI-937 and the pharmacokinetics of CI-937 in rats.
The anthracyclines daunorubicin and doxorubicin are cancer chemotherapy agents that complex DNA and are widely utilized… 
1989
1989
Lack of dose proportional pharmacokinetics for CI-937, an anthrapyrazole DNA intercalator, in mice.
The time course of CI-937, an anthrapyrazole DNA intercalator, was studied in plasma of mice after single intravenous doses of 1… 
1988
1988
Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells.
The insensitivity of colon tumors to various anticancer agents was studied in vitro. The activity of Adriamycin (ADR) in several… 
1986
1986
Effects of anthrapyrazole antineoplastic agents on lipid peroxidation.
Highly Cited
1985
Highly Cited
1985
In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles).
1985
1985
Establishment of adriamycin-resistant mammary adenocarcinoma 16/C in vitro and its sensitivity to the anthrapyrazoles CI-942 and CI-937
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)